BioMedNewsBreaks

TuesdayNov 03, 2020 12:00 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Appoints Experienced Innovator as VP of Strategy

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, has announced the appointment of a new vice president of strategy and business development. In her new role, Amy Griffith will be responsible for the company’s development of strategic and tactical initiatives, as well as new sales strategies. A veteran sales and innovation expert, Griffith has held executive management positions at leading technology companies and has also worked with start-ups, focusing on identifying and implementing strategic sales programs. With an expertise in the medical and health-care industry, Griffith has been deeply involved and brings impressive experience in strategic planning and…

Continue Reading

MondayNov 02, 2020 12:10 pm

BioMedNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Announces Q3 Growth of DetermaRx(TM) Physician Adoption, Testing Volume

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, recently provided an update on DetermaRx’s global growth and adoption. According to the update, DetermaRx is a treatment stratification test that identifies stage I-IIA non-small cell lung cancer (“NSCLC”) patients at high risk of recurrence, despite ostensibly curative surgery, who may benefit from the addition of chemotherapy. Since its January commercial launch in the U.S., DetermaRx has begun to be reimbursed by Medicare and multiple private payers and has seen rapid adoption across 67 hospitals. “We…

Continue Reading

MondayNov 02, 2020 11:49 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Secures $6.9M in Private Placement

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of non-systemic, recombinant therapies for gastrointestinal diseases, earlier this year announced the closing of a private placement financing (the “offering”). According to the update, AzurRx secured approximately $6.9 million in gross proceeds from certain accredited investors, with Alexander Capital LP acting as sole placement agent in the offering. The company intends to use net proceeds to eliminate short- and long-term indebtedness, as well as for general working capital purposes including product development. “We are very grateful for the continued support of our investors,” James Sapirstein, president and CEO of AzurRx said…

Continue Reading

FridayOct 30, 2020 1:50 pm

BioMedNewsBreaks – Oncocyte Corporation (NYSE American: OCX) Named Among the 2020 Best Places to Work in Orange County

Oncocyte (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, on Wednesday announced it has been named as one of the 2020 Best Places to Work in Orange County. Oncocyte ranked number four out of 40 in the medium-size company category. A project of the Orange County Business Journal and Best Companies Group, the awards program was created in 2009. “Great technologies and great strategies don’t do great things; great people accomplish great things,” said Ron Andrews, CEO of Oncocyte. “While our world of molecular diagnostics…

Continue Reading

FridayOct 30, 2020 12:23 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Launch of New Branding for Upcoming Combination Clinical Trials

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for cancer and diabetes patients, today announced the launch of new branding for its upcoming oncology clinical trials. The trials combine Genprex’s lead drug candidate, REQORSA(TM) (quaratusugene ozeplasmid), with AstraZeneca’s Tagrisso(R) (osimertinib), which received U.S. Food and Drug Administration (“FDA”) Fast Track Designation earlier this year, as well as the combination of REQORSA with Merck’s Keytruda(R) (pembrolizumab), for the treatment of non-small cell lung cancer (“NSCLC”). “We are enthusiastically preparing for our upcoming clinical trials and are excited to launch the adoption of this branding,” said Rodney Varner,…

Continue Reading

FridayOct 30, 2020 11:05 am

BioMedNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in BioWorld Article

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate.” The publication discusses the merging of Affamed Therapeutics Ltd., an emerging biopharmaceutical company focused on opthamology markets in Greater China and funded by the large global venture capital firm, CBC Group, and EverInsight Therapeutics Inc., a biopharmaceutical company focused on central nervous system disorders and also funded by CBC Group. EverInsight and VistaGen entered into an exclusive development and commercialization…

Continue Reading

ThursdayOct 29, 2020 1:16 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Announces Conditional FDA Acceptance of Proprietary Name for Lead Drug Candidate

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, has received conditional FDA acceptance of the proprietary name REQORSA(TM), its lead drug candidate for treatment of non-small cell lung cancer. The drug candidate was known previously by the laboratory designation GPX-001. The approval of the new name marks a critical branding milestone  for the company. Genprex’s REQORSA (pronounced “re-KORE-suh”) immunogene therapy features the company’s exclusive ONCOPREX(TM) nanoparticle delivery system that delivers cancer-fighting genes. The name will be resubmitted to the FDA for final review and approval after all required clinical trials…

Continue Reading

ThursdayOct 29, 2020 10:11 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Completion of Drug for Clinical Trials

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the central nervous system, has through its European manufacturer, BSP Pharmaceuticals S.p.A. ("BSP"), finished manufacturing its lead drug candidate for upcoming Phase 2 clinical trials. Berubicin is CNSP’s lead drug candidate for the treatment of glioblastoma multiforme (“GBM”), an aggressive form of brain cancer that is incurable. With the completion of the manufacturing, CNS Pharmaceuticals is now ready to kick off its planned Phase 2 clinical trials and file an Investigational New Drug Application ("IND"). CNSP contracted with two manufacturers…

Continue Reading

WednesdayOct 28, 2020 12:22 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Secures Financing to Fund Phase 2 Clinical Trials and Phase 3 Preparations

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company, in July entered into a convertible preferred stock and warrant securities purchase agreement with certain accredited and institutional investors relating to the private placement of certain shares of convertible preferred stock and warrants for cash and in exchange for certain outstanding promissory notes as described in a recent update. In addition, the company entered into an exchange addendum to the purchase agreement with certain investors, relating to the exchange, as consideration in the private placement, of approximately $6.9 million aggregate in principal amount, plus all accrued and unpaid interest thereon, of its outstanding…

Continue Reading

TuesdayOct 27, 2020 1:52 pm

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Positive Results in Ongoing Phase 2 Combination Therapy Trial with MS1819

AzurRx BioPharma (NASDAQ: AZRX), a clinical-stage biopharmaceutical company, recently announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a clinically meaningful improvement in the coefficient of fat absorption (“CFA”) at each of the three dose levels. No adverse safety events were reported and, additionally, patients showed improvements in the key secondary endpoints, including body weight, stool consistency and reductions in the number of bowel…

Continue Reading